The FDA approvedtebentafusp-tebn (Kimmtrak, Immunocore), a bispecific T-cell engager designed to redirect the immune system to recognize and kill cancerous cells, for the treatment of adults with unresectable or metastatic uveal melanoma.
Tabentafusp-tebn is the first T-cell receptor (TCR) therapeutic to receive regulatory approval from the FDA and the first bispecific T-cell engager approved to treat a solid tumor, according to Immunocore. It also is the only therapy approved to treat this rare